FDA Expands Approval of Rituxan as Remission Maintenance Treatment for GPA and MPA Patients – ANCA Vasculitis News

FDA Expands Approval of Rituxan as Remission Maintenance Treatment for GPA and MPA Patients – ANCA Vasculitis News

FDA Expands Approval of Rituxan as Remission Maintenance Treatment for GPA and MPA Patients – ANCA Vasculitis News
Published on 2018-10-23